Reports from BioMarin Pharmaceutical Inc. Advance Knowledge in Gene Therapy (Health Insurance Coverage and Switching Among People With Hemophilia a In the United States): Biotechnology – Gene Therapy
2022 MAR 30 (NewsRx) -- By a
Financial supporters for this research include
The news reporters obtained a quote from the research from
According to the news reporters, the research concluded: “These findings suggest that should breakthrough treatments be approved, payers would likely be able to realize substantial cost savings associated with avoiding tong-term prophylactic therapies during the several years after treatment.”
This research has been peer-reviewed.
For more information on this research see: Health Insurance Coverage and Switching Among People With Hemophilia a In
Our news correspondents report that additional information may be obtained by contacting
The direct object identifier (DOI) for that additional information is: https://doi.org/10.18553/jmcp.2021.21311. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
OXBRIDGE RE HOLDINGS LTD – 10-K – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MARPAI, INC. REPORTS THE FOURTH QUARTER AND YEAR END 2021 RESULTS
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News